---
title: Stress Ulcer Prophylaxis
layout: diseases
author: Corbin Cox
last-updated: 2018-12-23
created: 2018-12-23
toc: true
common: false
---
# Tx
* Some evidence benefits of SUP do not outweigh risks[^barletta2016]
* Treatment with PPIs, H2RAs, or Sucralafate is generally consider equivalent and is chosen based upon institutional preference and convenience, along with individual pt considerations[^barletta2016]
* ASHP recommends initiating with &ge; 1 major risk factor or &ge; 2 minor risk factors

Indications[^erstad1999]
{: .caption}

|Major Risk Factors|Minor Risk Factors|
|---|---|
|Coagulopathy (INR &gt; 1.5, Pmts &lt; 50k, or aPTT &gt; 2x ULN)|Sepsis|
|Expected Mechanical Ventilation &ge; 48hr|ICU &gt; 7d|
|Hx of GI ulceration / bleeding w/i 1yr|Occult bleeding &ge; 6d|
|GCS &le; 10|GCs &gt; 250mg hydrocortisone equivalent|
|Burns &gt; 35% BSA||
|Partial Hepatectomy||
|Multiple Trauma||
|Hepatic Failure||
|Spinal Cord Injuries||

Initial Dosing[^erstad1999]
{: .caption}

| Drug       | Normal Renal Fx                                   | Impaired Renal Fx                                      |
| ---------- | ------------------------------------------------- | ------------------------------------------------------ |
| Cimetidine | 300mg PO/IV QID<br />50mg/hr IV                   | &lt; 30: 300mg BID or 25 mg/hr                         |
| Famotidine | 20mg PO/IV BID<br />1.7mg/hr IV                   | &lt; 30: 20mg QD or 0.85 mg/hr                         |
| Ranitidine | 150mg PO BID<br />50mg IV Q4-6H<br />6.25mg/hr IV | &lt; 50: 150mg PO QD-BID, 50mg IV Q12-24H, or 2-4mg/hr |
| Omeprazole | 40mg load then 20-40mg QD                         | No adjustment                                          |
| Sucralfate | 1g QID                                            | No adjustment                                          |


# References
{% include sources.md %}